Literature DB >> 9582085

Sex hormone-induced prostatic carcinogenesis in the noble rat: the role of insulin-like growth factor-I (IGF-I) and vascular endothelial growth factor (VEGF) in the development of prostate cancer.

Y Z Wang1, Y C Wong.   

Abstract

BACKGROUND: Despite extensive effort, the mechanisms of prostate carcinogenesis are still unknown. We report on a modified method which enabled us to induce a high incidence of prostate carcinogenesis in the Noble rat and examined the role of insulin-like growth factor-1 (IGF-1) and vascular endothelial growth factor (VEGF) and their receptors during sex hormone-induced prostate carcinogenesis.
METHODS: Noble rats were implanted subcutaneously with a combination of testosterone and estradiol capsules for up to 12 months. Animals were sacrificed starting at 2 months after implantation, and the prostate gland was removed for histopathological and immunohistochemical studies.
RESULTS: The results showed that hyperplasia/dysplasia was detected as early as 2 months after treatment, while carcinoma in situ was induced in 4 months and adenocarcinoma in 7 months. Our data suggest that IGF-1, produced by stromal cells in hyperplasia, exerted its effects, through a paracrine mode, on epithelial cells which were IGF-1 receptor (IGF-1R)-positive. The production of IGF-1 appeared to switch to epithelial cells in adenocarcinoma, through which it regulated tumor cell growth via autocrine mode by binding to IGF-1R of carcinoma cells. On the other hand, VEGF was overexpressed in hyperplastic/dysplastic and carcinoma cells, while VEGF-R was detected in endothelial cells. The results suggest that overexpression of VEGF in deranged epithelia and arterial muscle cells may exert its influence on stromal angiogenesis and abnormal growth of prostate gland.
CONCLUSIONS: A modified Noble rat model with a high incidence of prostate carcinogenesis has been developed. Using this model, we have further established that IGF-1 and VEGF may be the critical regulators in mediating epithelial-stromal interactions in sex hormone-induced prostate carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9582085     DOI: 10.1002/(sici)1097-0045(19980515)35:3<165::aid-pros2>3.0.co;2-g

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  27 in total

Review 1.  Clinical use of somatomedin-1: yes or no?

Authors:  Z Laron
Journal:  Paediatr Drugs       Date:  1999 Jul-Sep       Impact factor: 3.022

2.  Apigenin attenuates insulin-like growth factor-I signaling in an autochthonous mouse prostate cancer model.

Authors:  Sanjeev Shukla; Gregory T MacLennan; Pingfu Fu; Sanjay Gupta
Journal:  Pharm Res       Date:  2011-12-03       Impact factor: 4.200

3.  Endometriotic cells exhibit metaplastic change and oxidative DNA damage as well as decreased function, compared to normal endometrium.

Authors:  M Slater; G Quagliotto; M Cooper; C R Murphy
Journal:  J Mol Histol       Date:  2005-05       Impact factor: 2.611

Review 4.  Cytokine and endocrine signaling in prostate cancer.

Authors:  J Puente Vazquez; E Grande Pulido; L M Anton Aparicio
Journal:  Med Oncol       Date:  2011-08-20       Impact factor: 3.064

Review 5.  Estrogens and prostate cancer: etiology, mediators, prevention, and management.

Authors:  Shuk-Mei Ho; Ming-Tsung Lee; Hung-Ming Lam; Yuet-Kin Leung
Journal:  Endocrinol Metab Clin North Am       Date:  2011-07-07       Impact factor: 4.741

6.  Antiangiogenic therapy effects on age-associated matrix metalloproteinase-9 (MMP-9) and insulin-like growth factor receptor-1 (IGFR-1) responses: a comparative study of prostate disorders in aged and TRAMP mice.

Authors:  Fabio Montico; Larissa Akemi Kido; Amanda Cia Hetzl; Raísa Mistieri Lorencini; Eduardo Marcelo Cândido; Valéria Helena Alves Cagnon
Journal:  Histochem Cell Biol       Date:  2014-02-22       Impact factor: 4.304

Review 7.  Testosterone therapy and prostate cancer--safety concerns are well founded.

Authors:  Laurence Klotz
Journal:  Nat Rev Urol       Date:  2015-01       Impact factor: 14.432

Review 8.  Growth hormone and prostate cancer: guilty by association?

Authors:  A Grimberg; P Cohen
Journal:  J Endocrinol Invest       Date:  1999       Impact factor: 4.256

Review 9.  The insulin-like growth factor system as a potential therapeutic target in gastrointestinal stromal tumors.

Authors:  Martin G Belinsky; Lori Rink; Kathy Q Cai; Michael F Ochs; Burton Eisenberg; Min Huang; Margaret von Mehren; Andrew K Godwin
Journal:  Cell Cycle       Date:  2008-10-07       Impact factor: 4.534

10.  Regulation of vascular endothelial growth factor (VEGF) splicing from pro-angiogenic to anti-angiogenic isoforms: a novel therapeutic strategy for angiogenesis.

Authors:  Dawid G Nowak; Elianna Mohamed Amin; Emma S Rennel; Coralie Hoareau-Aveilla; Melissa Gammons; Gopinath Damodoran; Masatoshi Hagiwara; Steven J Harper; Jeanette Woolard; Michael R Ladomery; David O Bates
Journal:  J Biol Chem       Date:  2009-11-11       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.